METHODS: The study encompassed a cohort of patients diagnosed with Hepatocellular Carcinoma (HCC). Diagnosis was established via contrast-enhanced computer tomography or magnetic resonance imaging that identified LI-RADS-5 nodules in conjunction with historical liver disease and elevated alpha-fetoprotein (AFP) levels or via histological examination confirming positivity for glypican3, heat shock protein 70, and glutamine synthetase. The study detailed the liver disease etiology, LI-RADS scores, characteristics and dimensions of HCC nodules, serum AFP concentrations, Edmondson-Steiner grading, and the expression of programmed cell death ligand 1 (PD-L1) in the tumor cells.
RESULTS: Among the study\'s cohort of Hepatocellular Carcinoma (HCC) patients, a portion had not received any prior treatments, while the remainder experienced local HCC recurrence following trans-arterial chemoembolization or radiofrequency ablation. Observations indicated elevated alpha-fetoprotein (AFP) levels in those who had not undergone any previous interventions, showing statistical significance. The Edmondson-Steiner classification predominantly identified grade III differentiation across patients, irrespective of their treatment history. Furthermore, an increase in intra-tumoral programmed cell death ligand 1 (PD-L1) expression was noted in patients who had not been subjected to previous therapies.
CONCLUSIONS: Liver biopsy offers valuable insights for patients with Hepatocellular Carcinoma (HCC), assisting in the tailoring of immune therapy strategies, particularly in cases of recurrence following prior local interventions.
方法:该研究包括一组诊断为肝细胞癌(HCC)的患者。诊断是通过对比增强计算机断层扫描或磁共振成像确定的LI-RADS-5结节与历史肝病和甲胎蛋白(AFP)水平升高或通过组织学检查确认的阳性为Glypican3,热休克蛋白70和谷氨酰胺合成酶。该研究详细介绍了肝病的病因,LI-RADS得分,肝癌结节的特征和尺寸,血清AFP浓度,Edmondson-Steiner评分,以及程序性细胞死亡配体1(PD-L1)在肿瘤细胞中的表达。
结果:在研究的肝细胞癌(HCC)患者队列中,一部分之前没有接受过任何治疗,而其余患者在经肝动脉化疗栓塞或射频消融后出现局部HCC复发。观察结果表明,在那些没有经历过任何干预措施的人中,甲胎蛋白(AFP)水平升高。显示统计学意义。Edmondson-Steiner分类主要确定患者的III级分化,不管他们的治疗历史。此外,在以前未接受过治疗的患者中,肿瘤内程序性细胞死亡配体1(PD-L1)表达增加.
结论:肝活检为肝细胞癌(HCC)患者提供了有价值的见解,协助定制免疫治疗策略,特别是在先前的局部干预后复发的病例。